The investigators aim to further the understanding of environmental factors that underlie the development of Type 1 diabetes (T1D) and the post-onset disease trajectory. Dysbiosis, defined as alterations in intestinal microbiota composition and function, has been hypothesized to increase the risk of developing T1D in those with genetic susceptibility. Dysbiosis may result from modern dietary habits, such as broad consumption of the highly processed Western Diet, or by widespread use of antibiotics. Here, the investigators propose to examine the impact of dysbiosis on the endogenous innate inflammatory state that potentiates T1D progression. The investigators hypothesize that probiotic-induced alterations in the intestinal microbiota may favorably alter the post-onset disease state.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
43
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Effect of Multistrain Probiotic on Immune System Inflammation as measured by plasma transcription analysis
Investigators will examine the effect of multistrain probiotic supplementation on the endogenous innate inflammatory state in youth newly diagnosed with T1D, as measured by plasma-induced transcription analysis. The investigators hypothesize that the participants receiving the probiotic will have less inflammation (as measured by transcriptional analysis) than the participants in the placebo group.
Time frame: 3 years (duration of study)
C-peptide decline
Investigators will examine the effect of multistrain probiotic supplementation on the post-onset rate of C-peptide decline (a measure of beta cell health)
Time frame: 3 years (duration of study)
Effect of Multistrain Probiotic on broader Immune System Effects as measured by plasma-induced transcriptional analyses
Investigators will examine the effect of multistrain probiotic supplementation on changes to the plasma-induced transcriptional assay to assess for probiotic-specific immune effects. Plasma-induced transcriptional analyses will be compared before and after treatment with probiotic/placebo. The investigators hypothesize that the participants receiving the probiotic will see reduced inflammation (as measured by transcriptional analysis) while those that received the placebo will see no change or increased inflammation.
Time frame: 3 years (duration of study)
Cytokine Levels (a measure of inflammation) as measured by plasma analysis
Cytokine levels before and after treatment will be measured by plasma analysis. It is hypothesized that the levels of cytokines in the blood will be lower after treatment for the participants receiving the probiotic but not for those receiving the placebo.
Time frame: 3 years (duration of study)
Changes to intestinal bacteria as measured by stool analysis
Investigators will examine the effect of multistrain probiotic supplementation the composition of the intestinal microbiota
Time frame: 3 years (duration of study)
System-wide Effects as measured by systemic microbial antigen (a marker of intestinal permeability) as measured by plasma analysis
Gut leakiness will be measured by examining the levels of microbial antigens in the plasma before and after treatment and correlating these antigen levels with the changes in the composition of the gut bacteria. It is hypothesized that changes in antigen levels and gut bacteria will only be seen in the participants receiving the probiotic. It is further hypothesized that those with the greatest reduction in antigens will have the most significant changes in gut bacteria composition.
Time frame: 3 years (duration of study)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.